Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: Results from a randomised trial of exemestane vs megestrol acetate

Antonia Martinetti, Nicoletta Zilembo, Leonardo Ferrari, Giorgio Massimini, Anna Polli, Ignazia La Torre, Riccardo Giovanazzi, Paola Pozzi, Paolo Bidoli, Daniela De Candis, Ettore Seregni, Emilio Bombardieri, Emilio Bajetta

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The aim of this randomised study was to compare the effects of progestins and aromatase inactivators on bone remodelling markers and the components of insulin-like growth factor in patients with metastatic breast cancer. Within the framework of a large (769 patients), randomised double-blind clinical trial comparing exemestane (EXE) with megestrol acetate (MA), serum 17ß-estradiol (E2), estrone (E1), estrone sulphate (E1S), bone alkaline phosphatase (BAP), carboxy-terminal cross-linking telopeptide of type I collagen (ICTP) and the components of insulin-like growth factor (IGF) family (IGF-1, IGF-2 and IGFBP-3) were determined in 53 patients (24 randomised to EXE and 29 ramdomised to MA). After eight weeks of treatment, both ICTP and BAP increased (p2 and E1S was more pronounced in the EXE group (to, respectively, 11.2% and 9.9% of baseline values) than in the MA group (33.1% and 29.7%). IGF-1 increased (p

Original languageEnglish
Pages (from-to)3485-3491
Number of pages7
JournalAnticancer Research
Volume23
Issue number4
Publication statusPublished - Jul 2003

Fingerprint

exemestane
Megestrol Acetate
Bone Remodeling
Somatomedins
Breast Neoplasms
Alkaline Phosphatase
Bone and Bones
Insulin-Like Growth Factor Binding Protein 3
Aromatase
Estrone
Progestins
Collagen Type I
Estradiol
Clinical Trials

Keywords

  • Aromatase inhibitors
  • Bone metabolism
  • Cancer
  • Exemestane
  • Insulin-like growth factors
  • Postmenopausal breast
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bone turnover markers and insulin-like growth factor components in metastatic breast cancer : Results from a randomised trial of exemestane vs megestrol acetate. / Martinetti, Antonia; Zilembo, Nicoletta; Ferrari, Leonardo; Massimini, Giorgio; Polli, Anna; La Torre, Ignazia; Giovanazzi, Riccardo; Pozzi, Paola; Bidoli, Paolo; De Candis, Daniela; Seregni, Ettore; Bombardieri, Emilio; Bajetta, Emilio.

In: Anticancer Research, Vol. 23, No. 4, 07.2003, p. 3485-3491.

Research output: Contribution to journalArticle

Martinetti, A, Zilembo, N, Ferrari, L, Massimini, G, Polli, A, La Torre, I, Giovanazzi, R, Pozzi, P, Bidoli, P, De Candis, D, Seregni, E, Bombardieri, E & Bajetta, E 2003, 'Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: Results from a randomised trial of exemestane vs megestrol acetate', Anticancer Research, vol. 23, no. 4, pp. 3485-3491.
Martinetti, Antonia ; Zilembo, Nicoletta ; Ferrari, Leonardo ; Massimini, Giorgio ; Polli, Anna ; La Torre, Ignazia ; Giovanazzi, Riccardo ; Pozzi, Paola ; Bidoli, Paolo ; De Candis, Daniela ; Seregni, Ettore ; Bombardieri, Emilio ; Bajetta, Emilio. / Bone turnover markers and insulin-like growth factor components in metastatic breast cancer : Results from a randomised trial of exemestane vs megestrol acetate. In: Anticancer Research. 2003 ; Vol. 23, No. 4. pp. 3485-3491.
@article{cbc5fee6871e45c68d054d60359d2074,
title = "Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: Results from a randomised trial of exemestane vs megestrol acetate",
abstract = "The aim of this randomised study was to compare the effects of progestins and aromatase inactivators on bone remodelling markers and the components of insulin-like growth factor in patients with metastatic breast cancer. Within the framework of a large (769 patients), randomised double-blind clinical trial comparing exemestane (EXE) with megestrol acetate (MA), serum 17{\ss}-estradiol (E2), estrone (E1), estrone sulphate (E1S), bone alkaline phosphatase (BAP), carboxy-terminal cross-linking telopeptide of type I collagen (ICTP) and the components of insulin-like growth factor (IGF) family (IGF-1, IGF-2 and IGFBP-3) were determined in 53 patients (24 randomised to EXE and 29 ramdomised to MA). After eight weeks of treatment, both ICTP and BAP increased (p2 and E1S was more pronounced in the EXE group (to, respectively, 11.2{\%} and 9.9{\%} of baseline values) than in the MA group (33.1{\%} and 29.7{\%}). IGF-1 increased (p",
keywords = "Aromatase inhibitors, Bone metabolism, Cancer, Exemestane, Insulin-like growth factors, Postmenopausal breast, Tamoxifen",
author = "Antonia Martinetti and Nicoletta Zilembo and Leonardo Ferrari and Giorgio Massimini and Anna Polli and {La Torre}, Ignazia and Riccardo Giovanazzi and Paola Pozzi and Paolo Bidoli and {De Candis}, Daniela and Ettore Seregni and Emilio Bombardieri and Emilio Bajetta",
year = "2003",
month = "7",
language = "English",
volume = "23",
pages = "3485--3491",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Bone turnover markers and insulin-like growth factor components in metastatic breast cancer

T2 - Results from a randomised trial of exemestane vs megestrol acetate

AU - Martinetti, Antonia

AU - Zilembo, Nicoletta

AU - Ferrari, Leonardo

AU - Massimini, Giorgio

AU - Polli, Anna

AU - La Torre, Ignazia

AU - Giovanazzi, Riccardo

AU - Pozzi, Paola

AU - Bidoli, Paolo

AU - De Candis, Daniela

AU - Seregni, Ettore

AU - Bombardieri, Emilio

AU - Bajetta, Emilio

PY - 2003/7

Y1 - 2003/7

N2 - The aim of this randomised study was to compare the effects of progestins and aromatase inactivators on bone remodelling markers and the components of insulin-like growth factor in patients with metastatic breast cancer. Within the framework of a large (769 patients), randomised double-blind clinical trial comparing exemestane (EXE) with megestrol acetate (MA), serum 17ß-estradiol (E2), estrone (E1), estrone sulphate (E1S), bone alkaline phosphatase (BAP), carboxy-terminal cross-linking telopeptide of type I collagen (ICTP) and the components of insulin-like growth factor (IGF) family (IGF-1, IGF-2 and IGFBP-3) were determined in 53 patients (24 randomised to EXE and 29 ramdomised to MA). After eight weeks of treatment, both ICTP and BAP increased (p2 and E1S was more pronounced in the EXE group (to, respectively, 11.2% and 9.9% of baseline values) than in the MA group (33.1% and 29.7%). IGF-1 increased (p

AB - The aim of this randomised study was to compare the effects of progestins and aromatase inactivators on bone remodelling markers and the components of insulin-like growth factor in patients with metastatic breast cancer. Within the framework of a large (769 patients), randomised double-blind clinical trial comparing exemestane (EXE) with megestrol acetate (MA), serum 17ß-estradiol (E2), estrone (E1), estrone sulphate (E1S), bone alkaline phosphatase (BAP), carboxy-terminal cross-linking telopeptide of type I collagen (ICTP) and the components of insulin-like growth factor (IGF) family (IGF-1, IGF-2 and IGFBP-3) were determined in 53 patients (24 randomised to EXE and 29 ramdomised to MA). After eight weeks of treatment, both ICTP and BAP increased (p2 and E1S was more pronounced in the EXE group (to, respectively, 11.2% and 9.9% of baseline values) than in the MA group (33.1% and 29.7%). IGF-1 increased (p

KW - Aromatase inhibitors

KW - Bone metabolism

KW - Cancer

KW - Exemestane

KW - Insulin-like growth factors

KW - Postmenopausal breast

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0042529168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042529168&partnerID=8YFLogxK

M3 - Article

C2 - 12926095

AN - SCOPUS:0042529168

VL - 23

SP - 3485

EP - 3491

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -